Cargando…
Reversal of deficits in aged skeletal muscle during disuse and recovery in response to treatment with a secrotome product derived from partially differentiated human pluripotent stem cells
Aged individuals are at risk to experience slow and incomplete muscle recovery following periods of disuse atrophy. While several therapies have been employed to mitigate muscle mass loss during disuse and improve recovery, few have proven effective at both. Therefore, the purpose of this study was...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8602548/ https://www.ncbi.nlm.nih.gov/pubmed/34427856 http://dx.doi.org/10.1007/s11357-021-00423-0 |
_version_ | 1784601598942511104 |
---|---|
author | Fix, Dennis K. Mahmassani, Ziad S. Petrocelli, Jonathan J. de Hart, Naomi M.M.P. Ferrara, Patrick J. Painter, Jessie S. Nistor, Gabriel Lane, Thomas E. Keirstead, Hans S. Drummond, Micah J. |
author_facet | Fix, Dennis K. Mahmassani, Ziad S. Petrocelli, Jonathan J. de Hart, Naomi M.M.P. Ferrara, Patrick J. Painter, Jessie S. Nistor, Gabriel Lane, Thomas E. Keirstead, Hans S. Drummond, Micah J. |
author_sort | Fix, Dennis K. |
collection | PubMed |
description | Aged individuals are at risk to experience slow and incomplete muscle recovery following periods of disuse atrophy. While several therapies have been employed to mitigate muscle mass loss during disuse and improve recovery, few have proven effective at both. Therefore, the purpose of this study was to examine the effectiveness of a uniquely developed secretome product (STEM) on aged skeletal muscle mass and function during disuse and recovery. Aged (22 months) male C57BL/6 were divided into PBS or STEM treatment (n = 30). Mice within each treatment were assigned to either ambulatory control (CON; 14 days of normal cage ambulation), 14 days of hindlimb unloading (HU), or 14 days of hindlimb unloading followed by 7 days of recovery (recovery). Mice were given an intramuscular delivery into the hindlimb muscle of either PBS or STEM every other day for the duration of their respective treatment group. We found that STEM-treated mice compared to PBS had greater soleus muscle mass, fiber cross-sectional area (CSA), and grip strength during CON and recovery experimental conditions and less muscle atrophy and weakness during HU. Muscle CD68 +, CD11b + and CD163 + macrophages were more abundant in STEM-treated CON mice compared to PBS, while only CD68 + and CD11b + macrophages were more abundant during HU and recovery conditions with STEM treatment. Moreover, STEM-treated mice had lower collagen IV and higher Pax7 + cell content compared to PBS across all experimental conditions. As a follow-up to examine the cell autonomous role of STEM on muscle, C2C12 myotubes were given STEM or horse serum media to examine myotube fusion/size and effects on muscle transcriptional networks. STEM-treated C2C12 myotubes were larger and had a higher fusion index and were related to elevated expression of transcripts associated with extracellular matrix remodeling. Our results demonstrate that STEM is a unique cocktail that possesses potent immunomodulatory and cytoskeletal remodeling properties that may have translational potential to improve skeletal muscle across a variety of conditions that adversely effect aging muscle. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11357-021-00423-0. |
format | Online Article Text |
id | pubmed-8602548 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-86025482021-12-02 Reversal of deficits in aged skeletal muscle during disuse and recovery in response to treatment with a secrotome product derived from partially differentiated human pluripotent stem cells Fix, Dennis K. Mahmassani, Ziad S. Petrocelli, Jonathan J. de Hart, Naomi M.M.P. Ferrara, Patrick J. Painter, Jessie S. Nistor, Gabriel Lane, Thomas E. Keirstead, Hans S. Drummond, Micah J. GeroScience Original Article Aged individuals are at risk to experience slow and incomplete muscle recovery following periods of disuse atrophy. While several therapies have been employed to mitigate muscle mass loss during disuse and improve recovery, few have proven effective at both. Therefore, the purpose of this study was to examine the effectiveness of a uniquely developed secretome product (STEM) on aged skeletal muscle mass and function during disuse and recovery. Aged (22 months) male C57BL/6 were divided into PBS or STEM treatment (n = 30). Mice within each treatment were assigned to either ambulatory control (CON; 14 days of normal cage ambulation), 14 days of hindlimb unloading (HU), or 14 days of hindlimb unloading followed by 7 days of recovery (recovery). Mice were given an intramuscular delivery into the hindlimb muscle of either PBS or STEM every other day for the duration of their respective treatment group. We found that STEM-treated mice compared to PBS had greater soleus muscle mass, fiber cross-sectional area (CSA), and grip strength during CON and recovery experimental conditions and less muscle atrophy and weakness during HU. Muscle CD68 +, CD11b + and CD163 + macrophages were more abundant in STEM-treated CON mice compared to PBS, while only CD68 + and CD11b + macrophages were more abundant during HU and recovery conditions with STEM treatment. Moreover, STEM-treated mice had lower collagen IV and higher Pax7 + cell content compared to PBS across all experimental conditions. As a follow-up to examine the cell autonomous role of STEM on muscle, C2C12 myotubes were given STEM or horse serum media to examine myotube fusion/size and effects on muscle transcriptional networks. STEM-treated C2C12 myotubes were larger and had a higher fusion index and were related to elevated expression of transcripts associated with extracellular matrix remodeling. Our results demonstrate that STEM is a unique cocktail that possesses potent immunomodulatory and cytoskeletal remodeling properties that may have translational potential to improve skeletal muscle across a variety of conditions that adversely effect aging muscle. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11357-021-00423-0. Springer International Publishing 2021-08-24 /pmc/articles/PMC8602548/ /pubmed/34427856 http://dx.doi.org/10.1007/s11357-021-00423-0 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Original Article Fix, Dennis K. Mahmassani, Ziad S. Petrocelli, Jonathan J. de Hart, Naomi M.M.P. Ferrara, Patrick J. Painter, Jessie S. Nistor, Gabriel Lane, Thomas E. Keirstead, Hans S. Drummond, Micah J. Reversal of deficits in aged skeletal muscle during disuse and recovery in response to treatment with a secrotome product derived from partially differentiated human pluripotent stem cells |
title | Reversal of deficits in aged skeletal muscle during disuse and recovery in response to treatment with a secrotome product derived from partially differentiated human pluripotent stem cells |
title_full | Reversal of deficits in aged skeletal muscle during disuse and recovery in response to treatment with a secrotome product derived from partially differentiated human pluripotent stem cells |
title_fullStr | Reversal of deficits in aged skeletal muscle during disuse and recovery in response to treatment with a secrotome product derived from partially differentiated human pluripotent stem cells |
title_full_unstemmed | Reversal of deficits in aged skeletal muscle during disuse and recovery in response to treatment with a secrotome product derived from partially differentiated human pluripotent stem cells |
title_short | Reversal of deficits in aged skeletal muscle during disuse and recovery in response to treatment with a secrotome product derived from partially differentiated human pluripotent stem cells |
title_sort | reversal of deficits in aged skeletal muscle during disuse and recovery in response to treatment with a secrotome product derived from partially differentiated human pluripotent stem cells |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8602548/ https://www.ncbi.nlm.nih.gov/pubmed/34427856 http://dx.doi.org/10.1007/s11357-021-00423-0 |
work_keys_str_mv | AT fixdennisk reversalofdeficitsinagedskeletalmuscleduringdisuseandrecoveryinresponsetotreatmentwithasecrotomeproductderivedfrompartiallydifferentiatedhumanpluripotentstemcells AT mahmassaniziads reversalofdeficitsinagedskeletalmuscleduringdisuseandrecoveryinresponsetotreatmentwithasecrotomeproductderivedfrompartiallydifferentiatedhumanpluripotentstemcells AT petrocellijonathanj reversalofdeficitsinagedskeletalmuscleduringdisuseandrecoveryinresponsetotreatmentwithasecrotomeproductderivedfrompartiallydifferentiatedhumanpluripotentstemcells AT dehartnaomimmp reversalofdeficitsinagedskeletalmuscleduringdisuseandrecoveryinresponsetotreatmentwithasecrotomeproductderivedfrompartiallydifferentiatedhumanpluripotentstemcells AT ferrarapatrickj reversalofdeficitsinagedskeletalmuscleduringdisuseandrecoveryinresponsetotreatmentwithasecrotomeproductderivedfrompartiallydifferentiatedhumanpluripotentstemcells AT painterjessies reversalofdeficitsinagedskeletalmuscleduringdisuseandrecoveryinresponsetotreatmentwithasecrotomeproductderivedfrompartiallydifferentiatedhumanpluripotentstemcells AT nistorgabriel reversalofdeficitsinagedskeletalmuscleduringdisuseandrecoveryinresponsetotreatmentwithasecrotomeproductderivedfrompartiallydifferentiatedhumanpluripotentstemcells AT lanethomase reversalofdeficitsinagedskeletalmuscleduringdisuseandrecoveryinresponsetotreatmentwithasecrotomeproductderivedfrompartiallydifferentiatedhumanpluripotentstemcells AT keirsteadhanss reversalofdeficitsinagedskeletalmuscleduringdisuseandrecoveryinresponsetotreatmentwithasecrotomeproductderivedfrompartiallydifferentiatedhumanpluripotentstemcells AT drummondmicahj reversalofdeficitsinagedskeletalmuscleduringdisuseandrecoveryinresponsetotreatmentwithasecrotomeproductderivedfrompartiallydifferentiatedhumanpluripotentstemcells |